Electronic Arts Inc. vs 10X Genomics Inc — how do they compare? Electronic Arts Inc. trades at $207.31 (market cap $51.97B), while 10X Genomics Inc trades at $45.51 (market cap $5.81B). The key difference: Electronic Arts Inc. is far larger — about 8.9× 10X Genomics Inc's market cap, and Electronic Arts Inc. pays a 0.37% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| EA | TXG | |
|---|---|---|
Market Cap | $51.97B | $5.81B |
Sector | Technology | Health |
52-Week High | $207.27 | $45.80 |
52-Week Low | $147.79 | $11.34 |
Enterprise Value | $50.54B | $5.35B |
Dividend Yield | 0.37% | — |
Signals from Pluang's Aura AI — not financial advice
Electronic Arts (EA) trades at $206.65, showing modest daily gains of 0.15%. The stock exhibits a bullish technical structure with moving averages aligned positively, though oscillators signal caution with RSI levels above 70. Fundamentally, EA maintains strong profitability with 78.97% gross margins and 11.78% net income margins, but valuation metrics appear elevated with a P/E of 59.05 and P/S of 6.96. Recent business developments include the successful launch of EA SPORTS College Football 27 and the introduction of EA Advertising platform for in-game brand integration.
The outlook balances strong franchise execution against valuation concerns. Investment opportunities stem from EA's dominant gaming portfolio, recurring revenue streams, and new advertising monetization. Key risks include recent earnings misses, potential regulatory scrutiny of the rumored $55 billion Saudi acquisition (Reuters, June 24, 2026), and stretched valuation multiples that may limit near-term upside despite analyst consensus leaning positive.
TXG is trading at $45.80, up 9.65% today, showing strong momentum despite mixed analyst sentiment. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company continues to report revenue growth with improving margins, narrowing losses from -$166M in 2022 to -$44M in 2025. Recent developments include strategic acquisitions and research collaborations that strengthen its life sciences technology position.
The outlook remains cautiously optimistic as TXG demonstrates operational improvement and strategic positioning in genomics technology. Key opportunities include continued margin expansion and platform adoption, while risks involve persistent profitability challenges and competitive pressures. Analyst consensus shows divided opinions with a $37.71 price target below current levels, suggesting potential near-term volatility despite long-term growth prospects.
Trailing returns across standard periods
Latest headlines on both assets
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →